Replimune Group Q3 EPS Estimate Boosted by HC Wainwright

Replimune Group, Inc. (NASDAQ:REPL) – Stock analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for shares of Replimune Group in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.73) for the quarter, up from their prior estimate of ($0.79). HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07.

Other equities research analysts have also issued research reports about the company. Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Performance

Replimune Group stock opened at $11.40 on Friday. The firm has a fifty day simple moving average of $11.44 and a two-hundred day simple moving average of $9.50. Replimune Group has a twelve month low of $4.92 and a twelve month high of $12.97. The company has a market capitalization of $779.99 million, a PE ratio of -3.74 and a beta of 1.19. The company has a quick ratio of 13.46, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently bought and sold shares of the business. Quest Partners LLC increased its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Algert Global LLC grew its position in Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after purchasing an additional 4,340 shares during the last quarter. Creative Planning increased its stake in Replimune Group by 28.7% during the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after acquiring an additional 5,410 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.